Literature DB >> 11296968

Lipodystrophy in patients with juvenile dermatomyositis--evaluation of clinical and metabolic abnormalities.

C Huemer1, H Kitson, P N Malleson, S Sanderson, M Huemer, D A Cabral, J P Chanoine, R E Petty.   

Abstract

OBJECTIVE: Lipodystrophy and associated metabolic abnormalities are being increasingly recognized as complications of juvenile dermatomyositis (JDM). We investigated the prevalence of lipodystrophy and the extent of metabolic abnormalities related to lipoatrophic diabetes mellitus in patients with JDM.
METHODS: Twenty patients with JDM were evaluated for evidence of lipodystrophy and associated lipoatrophic diabetes mellitus. All patients underwent clinical assessment, laboratory investigations, and metabolic studies (oral glucose tolerance test, lipid studies, insulin antibodies).
RESULTS: We found clinical evidence of lipodystrophy and lipoatrophic diabetes mellitus in 4 of 20 patients with JDM and metabolic abnormalities known to be associated with lipodystrophy in another 8 patients. The 20 patients with JDM were categorized as follows: Group 1 (Patients 1-4) consisted of patients with lipodystrophy and either diabetes mellitus (2 patients) or impaired glucose tolerance (2 patients); Group 2 (Patients 5-12): no lipodystrophy but abnormal glucose and/or lipid studies; Group 3 (Patients 13-20): no lipodystrophy and no abnormalities of glucose and lipid studies.
CONCLUSION: We found 25% of patients with JDM have lipodystrophy, and 50% present with hypertriglyceridemia and insulin resistance. Screening for metabolic abnormalities in JDM should be included in routine followup because of the effect of lipodystrophy on longterm prognosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11296968

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  15 in total

Review 1.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

Review 2.  Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going?

Authors:  Adam Huber; Brian M Feldman
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

Review 3.  Juvenile dermatomyositis.

Authors:  Michelle Batthish; Brian M Feldman
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

Review 4.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

5.  Metabolic abnormalities and cardiovascular risk factors in children with myositis.

Authors:  Kathleen Coyle; Kristina I Rother; Martina Weise; Alaa Ahmed; Frederick W Miller; Lisa G Rider
Journal:  J Pediatr       Date:  2009-07-29       Impact factor: 4.406

6.  Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis.

Authors:  Abdolreza Malek; Seyed-Reza Raeeskarami; Vahid Ziaee; Yahya Aghighi; Mohamad-Hassan Moradinejad
Journal:  Clin Rheumatol       Date:  2014-05-31       Impact factor: 2.980

7.  Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy.

Authors:  Jean Y Park; Angeline Y Chong; Elaine K Cochran; David E Kleiner; Michael J Haller; Desmond A Schatz; Phillip Gorden
Journal:  J Clin Endocrinol Metab       Date:  2007-10-16       Impact factor: 5.958

8.  Twelve years experience of juvenile dermatomyositis in North India.

Authors:  Surjit Singh; Arun Bansal
Journal:  Rheumatol Int       Date:  2005-09-15       Impact factor: 3.580

9.  Clinical characteristics and outcomes of juvenile and adult dermatomyositis.

Authors:  Sang-Jun Na; Seung Min Kim; Il Nam Sunwoo; Young-Chul Choi
Journal:  J Korean Med Sci       Date:  2009-07-30       Impact factor: 2.153

10.  Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity.

Authors:  April Bingham; Gulnara Mamyrova; Kristina I Rother; Elif Oral; Elaine Cochran; Ahalya Premkumar; David Kleiner; Laura James-Newton; Ira N Targoff; Janardan P Pandey; Danielle Mercatante Carrick; Nancy Sebring; Terrance P O'Hanlon; Maria Ruiz-Hidalgo; Maria Turner; Leslie B Gordon; Jorge Laborda; Steven R Bauer; Perry J Blackshear; Lisa Imundo; Frederick W Miller; Lisa G Rider
Journal:  Medicine (Baltimore)       Date:  2008-03       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.